medigraphic.com
ISSN 1561-2988 (Print)

2021, Number 3

<< Back Next >>

Rev Cubana Farm 2021; 54 (3)

Biopharmaceutical quality of 100 mg atenolol tablets

Pérez NA, Fernández SAJ, Parte GA, Fernández CM, Pérez RD, Cabrera PMÁ

Language: Spanish
References: 16
Page: 1-13
PDF size: 695.54 Kb.


ABSTRACT

Introduction: Atenolol is a cardio-selective β-blocker, which is widely used in the management of hypertension, angina pectoris, cardiac arrhythmias and acute myocardial infarction.
Objective: Determine the biopharmaceutical quality of multi-sources of oral administration containing 100 mg of atenolol.
Methods: Tablets of two national formulations were analyzed, one by wet way (AVH) and one by dry way (A-CD), and two imported (B and C). The tests carried out were: evaluation of labels and prospectuses, description of the tablets, average weight, hardness, friability, disintegration, identity and content of atenolol, uniformity of dosing units, dilution test and dilution profiles. Simultaneously, the performance of the chromatographic method for the quantification of the analyte in the in vitro dilution test was verified. To evaluate the drug´s kinetics release, different mathematical models were applied, including, the calculation of the efficiency of the dilution and the area under the curve.
Results: According to the technological and chemical evaluation carried out, all the products met the established quality specifications. It was demonstrated that the chromatographic method met the criteria established for the intended purpose. The A-VH tablets were classified as fast dilution, while the rest of the formulations as very fast dilution. A-CD and C imported tablets showed equal dissolution efficiency values and areas under the curves.
Conclusions: The imported formulations of 100 mg atenolol and the new formulation by direct compression present better biopharmaceutical quality than the wet formulation.


REFERENCES

  1. WHO. Multisource (generic) pharmaceutical products: guidelines onregistration requirements to establish interchangeability. Annex 6, WHO TechRep Ser No 1003. Geneva: WHO; 2017 p. 181-236. [acceso 10/01/2021].Disponible en:https://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_1003_full-version.pdf Acceso en: Febrero 2021

  2. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Moeller H, et al.Biowaiver monographs for immediate release solid oral dosage forms based onbiopharmaceutics classification system (BCS) literature data: verapamilhydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci.2004;93(6):1945-56. DOI: 10.1002/jps.20131

  3. Alnuhait M, Shammari A, Ahmed M, Obaidat A. In-vitro evaluation of somegeneric products of atenolol commonly sold in the Saudi market. Journal ofInnovations in Pharmaceuticals and Biological Sciences. 2016 [acceso10/01/2021];(2):12-19. Disponible en:http://www.jipbs.com/VolumeArticles/FullTextPDF/191_JIPBSV3I203.pdf

  4. Colectivo de autores. Cuadro Básico de Medicamentos; Médicas, C. N. de I. deC. Ed.; Editorial de Ciencias Médicas: La Habana, Cuba. 2019.

  5. Dharmalingam SR, Azizi M, Shanmugham S, Srikanth Meka V, Pei Se W.Comparative Quality Control Evaluation of Atenolol Tablets Marketed in KualaLumpur, Malaysia. British Journal of Pharmaceutical Research. 2014;4(13):1688-95. DOI: 10.9734/BJPR/2014/8813

  6. Usman S, Alam A, Nadeem N, Khawar R, Intesar S. Biowaiver Studies ofAtenolol Tablets (100 mg) - An Alternative to In Vivo Bioequivalence Studies.Natural Products Chemistry & Research. 2014;2:1-5. DOI: 10.4172/ 2329-6836.1000125

  7. Abdelkarim A, Mohammed A, Abdeen M. Assessment of Pharmaceutical QualityControl and In Vitro Equivalence of Various Brands of Atenolol (100 mg) TabletsAvailable in Sudanese Market Under Biowaiver Conditions. International Journalof Pharmaceutical Sciences and Research. 2015;6(6):2390-94. DOI:10.13040/IJPSR.0975-8232.6(6).2390-94

  8. Ahmed EM, Ibrahim ME, Magbool FF. In Vitro-In Vivo Bio-EquivalenceCorrelation Study of Atenolol, and its Brands of Immediate Release Tablet UnderBio-Waiver Conditions. Universal Journal of Pharmaceutical Research.2019;4(6):25-9. DOI: 10.22270/ujpr.v4i6.332

  9. Safila N, Huma D, Samreen A. Comparative study of different brands ofatenolol available in Karachi. Mintage Journal of Pharmaceutical & MedicalSciences. 2014 [acceso 11/01/2021];3(3):17-19. Disponible en:https://www.mjpms.in/articles/comparitive-study-of-different-brands-ofatenololavailable-in-karachi.pdf

  10. Shagufta N, Najia R, Rabia IY. Evaluation of pharmaceutical quality andbiowaiver study of atenolol tablets available in Karachi (Pakistan). Lat. Am. J.Pharm. 2017 [acceso 10/02/2021];36(10):2007-11. Disponible en:http://www.latamjpharm.org/resumenes/36/10/LAJOP_36_10_1_18.pdf

  11. Reddy NHS, Patnala S, Kanfer I. Investigation of Biowaivers for ImmediateRelease Formulations Containing BCS III Drugs, Acyclovir, Atenolol, andCiprofloxacin Hydrochloride, Using Dissolution Testing AAPS PharmSciTech.2017;18:424-31. DOI: 10.1208/s12249-016-0520-4

  12. Gaber D, Abdoun S, Maswadeh H, Alnassr E, Al Salamah M. Equivalence studyof inmediate release tablets of beta blocker drug Int J App Pharm. 2020;2: 53-59. DOI: https://doi.org/10.22159/ijap.2020v12i2.36477

  13. Miranda-Pérez de Alejo C, Fernández Cervera M, Reyes-Naranjo M, Cabrera-Pérez MA. Aplicación del sistema de clasificación biofarmacéutica al CuadroBásico de Medicamentos de Cuba: ¿bioequivalencia in vivo o disolución in vitro?.Rev. OFIL·ILAPHAR. 2020 [acceso 10/02/2021];30(4):91-300. Disponible en:https://dx.doi.org/10.4321/s1699-714x2020000400009

  14. Centro para el Control Estatal de la Calidad de los Medicamentos(CECMED). Regulación 14-09. Textos Para Materiales De Envase Impresos EInformación Para Medicamentos De Uso Humano De Producción Nacional. LaHabana: CECMED; 2009. [acceso 10/01/2021]. Disponible en:https://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/

  15. United States Pharmacopeia 40 Ed. (USP 40). United States Pharmacopoeia.US Pharmacopoeia Convention, Inc. Washington DC: USP 40. 2017. p. 632, 1225-6, 1408-29, 1952-60, 3168-9. [acceso 10/03/2021]. Disponible en:https://www.uspnf.com/official-text/proposal-statuscommentary/usp-40-nf-35

  16. Centro para el Control Estatal de la Calidad de los Medicamentos(CECMED). Anexo 1: Buenas Prácticas para Laboratorios de Control deMedicamentos. Validación de métodos analíticos. La Habana: CECMED; 2013. p.3-25. [acceso 10/01/2021]. Disponible en:https://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/




2020     |     www.medigraphic.com